Mineralys Therapeutics financials
$24.48−4.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$246.0M | -$45.3M | -$38.3M | -$41.1M | -$46.7M | -$44.4M | -$51.8M | -$60.1M | -$45.2M | -$35.4M | -$27.7M | -$26.3M |
| Net income | -$241.1M | -$39.3M | -$32.2M | -$36.9M | -$43.3M | -$42.2M | -$48.9M | -$56.3M | -$41.0M | -$31.5M | -$24.4M | -$22.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.85 | $-0.47 | $-0.40 | $-0.52 | $-0.66 | $-0.79 | $-0.98 | $-1.13 | $-0.83 | $-0.70 | $-0.61 | $-0.57 |
| EBITDA | -$246.0M | -$45.3M | -$38.3M | -$41.1M | -$46.7M | -$44.4M | -$51.8M | -$60.1M | -$45.2M | -$35.4M | -$27.7M | -$26.3M |
| Operating cash flow | -$32.6M | -$39.5M | -$37.9M | -$28.9M | -$30.2M | -$45.5M | -$66.8M | -$50.2M | -$30.1M | -$19.1M | -$29.0M | -$19.0M |
| Free cash flow | -$32.6M | -$39.5M | -$37.9M | -$28.9M | -$30.2M | -$45.5M | -$66.8M | -$50.2M | -$30.1M | -$19.2M | -$29.0M | -$19.0M |
| Diluted shares | 84.7M | 82.8M | 81.4M | 70.6M | 65.5M | 53.2M | 50.1M | 49.8M | 49.4M | 44.9M | 40.3M | 39.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $138.3M | $112.8M | $172.9M | $217.6M | $101.8M | $165.0M |
| Short-term investments | $523.1M | $533.3M | $483.7M | $376.0M | $223.1M | $178.0M |
| Total debt | $97.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $667.9M | $652.9M | $661.8M | $599.9M | $335.7M | $354.9M |
| Total liabilities | $116.9M | $14.7M | $15.1M | $23.5M | $22.2M | $13.4M |
| Shareholders' equity | $550.9M | $638.1M | $646.7M | $576.4M | $313.6M | $341.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology